Meeting
2020 Gastrointestinal Cancers Symposium
Association of KRAS and BRAF mutations with progression-free survival (PFS) with second-line FOLFIRI +/- regorafenib in metastatic colorectal cancer (mCRC).
Authors
Federico Innocenti
The University of North Carolina at Chapel Hill, Chapel Hill, NC
Federico Innocenti , Sara R. Selitsky , Joel S. Parker , James Todd Auman , Kelli Hammond , Sushant A. Patil , Hanna Kelly Sanoff , Michael Sangmin Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Translational Research
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 196)
Abstract #
196
Poster Bd #
J16
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real world effectiveness of regorafenib in heavily pretreated patients with metastatic colorectal cancer.
First Author: Anastasia Danilova
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Prognostic effect of RAS/BRAF mutations in patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Haisam Abid
Poster
2018 Gastrointestinal Cancers Symposium
Are BRAF mutated metastatic colorectal cancer (mCRC) tumors more responsive to VEGFR-2 blockage? Analysis of patient outcomes by RAS/RAF mutation status in the RAISE study—A global, randomized, double-blind, phase III study.
First Author: Takayuki Yoshino
Poster
2014 ASCO Annual Meeting
Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).
First Author: Marc Peeters